ME03325B - Inhibitor aurora a kinaze - Google Patents

Inhibitor aurora a kinaze

Info

Publication number
ME03325B
ME03325B MEP-2019-44A MEP201944A ME03325B ME 03325 B ME03325 B ME 03325B ME P201944 A MEP201944 A ME P201944A ME 03325 B ME03325 B ME 03325B
Authority
ME
Montenegro
Prior art keywords
kinaze
aurora
inhibitor
inhibitor aurora
Prior art date
Application number
MEP-2019-44A
Other languages
German (de)
English (en)
French (fr)
Inventor
James Robert Henry
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME03325B publication Critical patent/ME03325B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-44A 2014-11-14 2015-11-06 Inhibitor aurora a kinaze ME03325B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079742P 2014-11-14 2014-11-14
EP15798602.7A EP3218366B1 (en) 2014-11-14 2015-11-06 Aurora a kinase inhibitor
PCT/US2015/059390 WO2016077161A1 (en) 2014-11-14 2015-11-06 Aurora a kinase inhibitor

Publications (1)

Publication Number Publication Date
ME03325B true ME03325B (me) 2019-10-20

Family

ID=54697647

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-44A ME03325B (me) 2014-11-14 2015-11-06 Inhibitor aurora a kinaze

Country Status (41)

Country Link
US (2) US9637474B2 (me)
EP (2) EP3218366B1 (me)
JP (1) JP6159029B2 (me)
KR (1) KR101930182B1 (me)
CN (1) CN107108567B (me)
AR (1) AR102463A1 (me)
AU (1) AU2015347043B2 (me)
BR (1) BR112017007239B1 (me)
CA (1) CA2963473C (me)
CL (1) CL2017001209A1 (me)
CO (1) CO2017004784A2 (me)
CR (1) CR20170158A (me)
CY (2) CY1121334T1 (me)
DK (2) DK3473619T3 (me)
DO (1) DOP2017000111A (me)
EA (1) EA032102B1 (me)
EC (1) ECSP17029203A (me)
ES (2) ES2826448T3 (me)
HR (2) HRP20190324T1 (me)
HU (2) HUE043759T2 (me)
IL (1) IL251406B (me)
JO (1) JO3488B1 (me)
LT (2) LT3218366T (me)
ME (1) ME03325B (me)
MX (1) MX377560B (me)
MY (1) MY188313A (me)
NZ (1) NZ730771A (me)
PE (1) PE20170898A1 (me)
PH (1) PH12017500881A1 (me)
PL (1) PL3218366T3 (me)
PT (2) PT3218366T (me)
RS (2) RS60999B1 (me)
SG (1) SG11201703394RA (me)
SI (2) SI3218366T1 (me)
SV (1) SV2017005418A (me)
TN (1) TN2017000116A1 (me)
TR (1) TR201902686T4 (me)
TW (1) TWI693218B (me)
UA (1) UA117983C2 (me)
WO (1) WO2016077161A1 (me)
ZA (1) ZA201702199B (me)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52793A (fr) * 2018-05-29 2021-04-14 Taiho Pharmaceutical Co Ltd Agent antitumoral et méthode de traitement d'une tumeur
US20220000855A1 (en) * 2018-11-30 2022-01-06 Eli Lilly And Company An aurora a kinase inhibitor for use in the treatment of neuroblastoma
CN112239465A (zh) 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
MX2023013890A (es) 2021-05-24 2023-12-11 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
TW202321215A (zh) * 2021-07-28 2023-06-01 大陸商北京加科思新藥研發有限公司 Aurora a 選擇性抑制劑的多晶型及其用途
CN119546309A (zh) 2022-04-08 2025-02-28 伊莱利利公司 包括kras g12c抑制剂和aurora a抑制剂的治疗方法
JP2025538371A (ja) 2022-11-23 2025-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121039117A (zh) * 2023-05-05 2025-11-28 苏州信诺维医药科技股份有限公司 杂环类化合物、其药物组合物和其应用
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
MX2007005155A (es) * 2004-10-29 2007-06-26 Banyu Pharma Co Ltd Nuevos derivados de aminopiridina que tienen accion inhibidora selectiva de la aurora a.
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN102497863A (zh) * 2009-03-24 2012-06-13 Msdk.K.公司 具有Aurora A选择性抑制作用的新型氨基吡啶衍生物
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
HUE051530T2 (hu) 2021-03-01
ES2716732T3 (es) 2019-06-14
US20160137628A1 (en) 2016-05-19
CA2963473A1 (en) 2016-05-19
ZA201702199B (en) 2018-12-19
NZ730771A (en) 2018-07-27
PH12017500881B1 (en) 2017-11-06
HRP20201681T1 (hr) 2020-12-25
ES2826448T3 (es) 2021-05-18
EP3473619B1 (en) 2020-09-09
JO3488B1 (ar) 2020-07-05
KR101930182B1 (ko) 2018-12-17
LT3473619T (lt) 2020-11-10
TW201629038A (zh) 2016-08-16
BR112017007239B1 (pt) 2023-01-31
US10010540B2 (en) 2018-07-03
CO2017004784A2 (es) 2017-08-31
EA032102B1 (ru) 2019-04-30
HUE043759T2 (hu) 2019-09-30
EA201790838A1 (ru) 2017-12-29
CR20170158A (es) 2017-06-21
EP3218366B1 (en) 2019-01-09
PT3473619T (pt) 2020-11-11
TR201902686T4 (tr) 2019-03-21
MX377560B (es) 2025-03-10
SI3473619T1 (sl) 2020-10-30
PE20170898A1 (es) 2017-07-12
HRP20190324T1 (hr) 2019-04-19
PT3218366T (pt) 2019-04-01
EP3218366A1 (en) 2017-09-20
PL3218366T3 (pl) 2019-06-28
BR112017007239A2 (pt) 2017-12-19
TWI693218B (zh) 2020-05-11
DOP2017000111A (es) 2017-06-15
AR102463A1 (es) 2017-03-01
TN2017000116A1 (en) 2018-07-04
MY188313A (en) 2021-11-27
KR20170066623A (ko) 2017-06-14
UA117983C2 (uk) 2018-10-25
RS58347B1 (sr) 2019-03-29
SV2017005418A (es) 2018-10-09
ECSP17029203A (es) 2018-01-31
CY1121334T1 (el) 2020-05-29
LT3218366T (lt) 2019-04-10
EP3473619A1 (en) 2019-04-24
JP6159029B2 (ja) 2017-07-05
IL251406B (en) 2019-08-29
JP2016539942A (ja) 2016-12-22
CN107108567B (zh) 2020-01-10
CA2963473C (en) 2018-12-18
US20170119751A1 (en) 2017-05-04
RS60999B1 (sr) 2020-11-30
DK3218366T3 (en) 2019-04-01
SG11201703394RA (en) 2017-05-30
US9637474B2 (en) 2017-05-02
PH12017500881A1 (en) 2017-11-06
SI3218366T1 (sl) 2019-02-28
DK3473619T3 (da) 2020-09-21
IL251406A0 (en) 2017-05-29
CN107108567A (zh) 2017-08-29
AU2015347043A1 (en) 2017-05-04
WO2016077161A1 (en) 2016-05-19
MX2017006275A (es) 2017-08-14
EP3473619B8 (en) 2020-11-04
CY1123592T1 (el) 2022-03-24
AU2015347043B2 (en) 2018-03-22
CL2017001209A1 (es) 2018-01-12

Similar Documents

Publication Publication Date Title
NO2024007I1 (no) Elacestrant or a salt thereof
ME03325B (me) Inhibitor aurora a kinaze
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
HUE050732T2 (hu) Új vegyületek
LT3134402T (lt) 4-amino-imidazochinolino junginiai
DK3132111T3 (da) Borehulsredskab
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
BR112016030730A2 (pt) Composto
DE112015001664A5 (de) Betätigungsaktuator
HUE066987T2 (hu) Szelektív il-6-transz-szignalizációt gátló szert tartalmazó készítmények
BR112017006123A2 (pt) emulsões o/a
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
BR112017005751A2 (pt) emulsões o/a
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
BR112016027901A2 (pt) Compostos
DE112015001633A5 (de) Betätigungsaktuator
FR3021937B1 (fr) Servofrein a depression
TH1601003589A (th) ควินาโซลิน-thf-เอมีนที่เป็นตัวยับยั้ง pde1
FI10586U1 (fi) Rakennusosa
TH1501006052A (th) สารยับยั้ง bacei
TH1601001170B (th) เครื่องมือปฏิบัติงาน
UA31157S (uk) Саморіз
ITRA20140020U1 (it) Utensile
ITCH20140005U1 (it) Stappa water-wc